You are currently viewing AI In Pharma Market Set To Reach $11.12 Billion By 2030, Driven By Rising adoption of cloud-based applications and services by pharmaceutical companies
AI In Pharma Market Analysis

Market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights are among the key offerings featured in The Business Research Company’s 2026 market reports, designed to deliver more actionable and strategically valuable research.

What Is The AI In Pharma Market Size In 2026, And Where Is It Heading By 2030?

The AI in pharma market has witnessed substantial growth in recent times. This market is projected to expand from $3.78 billion in 2025 to reach $4.79 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 26.9%. Historically, this expansion has been driven by factors such as increased pharmaceutical R&D spending, the growing volume of biomedical data, the imperative for accelerated drug development, the integration of computational biology, and the increasing prevalence of chronic diseases.

The AI in pharma market is projected to experience substantial expansion over the coming years, reaching $11.12 billion by 2030, driven by a compound annual growth rate (CAGR) of 23.4%. This anticipated growth during the forecast period is fueled by factors such as the increasing adoption of precision medicine, the rise of AI-powered clinical trials, the demand for cost-effective drug discovery, the expansion of personalized therapies, and the integration of genomics data. Key trends expected during this period involve AI-driven drug discovery, optimization of clinical trials, predictive disease modeling, real-time patient data analytics, and automated research and development processes.

Request Your Free AI In Pharma Market Sample With Segment And Regional Data:

https://thebusinessresearchcompany.com/sample_request?id=49745935&type=smp&name=AI%20In%20Pharma%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

AI In Pharma Market Growth Drivers And Their Impact On Future Demand

The increasing integration of cloud-based applications and services by pharmaceutical companies is anticipated to drive the expansion of the AI in pharma market. Cloud-based drug discovery platforms represent an advanced approach to conducting research and development within the pharmaceutical sector. These platforms utilize data analytics and cloud computing technologies to improve drug discovery processes, providing an extensive array of tools and capabilities crucial for various aspects of drug research and identification. Such platforms enhance the efficiency, cost-effectiveness, and collaborative nature of these procedures. Pharmaceutical firms are key market participants and end-users of these platforms, which assist them in managing vast quantities of clinical, chemical, and biological data through secure storage solutions. For example, in relation to 2025, Eurostat, the European Union’s statistical office based in Luxembourg, reported that in 2023, 45% of EU businesses had acquired cloud computing services. Significantly, large enterprises demonstrated a greater inclination to adopt cloud solutions than SMEs, with 78% of large businesses utilizing cloud services compared to 44% of SMEs. Consequently, the expanding adoption of cloud-based applications and services by pharmaceutical companies is set to propel the AI in pharma market growth throughout the forecast period.

What Categories Define The AI In Pharma Market?

The AI in pharma market covered in this report is segmented –

1) By Technology: Context-Aware Processing, Natural Language Processing, Querying Method, Deep Learning

2) By Drug Type: Small Molecule, Large Molecules

3) By Application: Diagnosis, Clinical Trial Research, Drug Discovery, Research and Development, Epidemic Prediction

Subsegments:

1) By Context-Aware Processing: Real-Time Data Processing, Contextual Recommendation Systems, Adaptive Learning Systems

2) By Natural Language Processing (NLP): Text Analytics And Sentiment Analysis, Chatbots And Virtual Assistants, Document And Data Mining

3) By Querying Method: Structured Querying, Unstructured Querying, Semantic Search Technologies

4) By Deep Learning: Neural Networks For Drug Discovery, Image Recognition For Medical Imaging, Predictive Analytics Models

What New Developments Are Emerging In The AI In Pharma Market?

Major companies operating in the AI in pharma market are prioritizing the development of technological advancements, including AI-powered medical consultation enhancement tools, to improve diagnostic accuracy, streamline clinical workflows, and support timely decision-making for healthcare professionals. These AI-powered medical consultation enhancement tools utilize large language models (LLMs) to generate clinical summaries, automate documentation, and interpret patient-provided information, thereby optimizing physician efficiency. For instance, in October 2023, Ubie Inc., a Japan-based medical AI startup, introduced a generative AI-driven feature for doctors that simplifies medical record documentation and summarizes patient findings. This feature, known as the medical interview summary function, employs an LLM to automatically condense 20–30 patient responses related to symptoms and lifestyle habits, which are collected through the Ubie Medical Navi platform. By presenting concise summaries directly on the doctor’s screen, the tool allows physicians to quickly understand patient concerns, reduce administrative burden, and enhance the overall quality and speed of medical consultations.

Major Players Driving Competition In The AI In Pharma Market

Major companies operating in the AI in pharma market are Concerto HealthAI; Alphabet Inc.; OWKIN; Nvidia Corporation; PathAI; Insilico Medicine; Exscientia; Microsoft Corporation; XtalPi; Intel; Standigm; Takeda Pharmaceutical Company Ltd.; Otsuka Pharmaceutical Co. Ltd.; DeepMind; GlaxoSmithKline; Sanofi; Bayer; Renalytix AI; Merck; AstraZeneca; Iktos; Benevolent AI; Novartis; Ardigen; Botkin; Webiomed; Care Mentor AI; Diagnocat; IBM Corporation; Atomwise Inc.; Cloud Pharmaceuticals; Bioage; NuMedii; Envisagenics; Aria Pharmaceuticals; Verge Genomics; Berg LLC; Cyclica; IQVIA; Roche; Pfizer; PRA Health Sciences; Oncora Medical; Recursion Pharmaceuticals Inc.; Nucleai; Pepticom; Rology; hearX Group; iNNOHEALTH Technology Solutions

View The Comprehensive AI In Pharma Market Analysis:

https://thebusinessresearchcompany.com/report/ai-in-pharma-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

AI In Pharma Market Regional Leaders: Insights From The 2026 Report

North America was the largest region in the AI in pharma market in 2025. The regions covered in the AI in pharma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model